Answers are grounded in this paper and cite their sources.
In this paper, we have developed a light-activated single component fluorescent organic nanoparticles for synergistic combination therapy (chemo-photodynamic therapy) utilizing the combined benefits of aggregation-induced emission (AIE) and excited-state intramolecular proton transfer (ESIPT) phenomena. The single-component organic nanoparticles were synthesized by coupling tetraphenylethylene (TPE) moiety with the p-hydroxy phenacyl-chlorambucil conjugate. Then, tetraphenylene-p-hydroxyphenacyl-chlorambucil (TPE-pHP-Cbl) nanoparticles were prepared by a simple reprecipitation technique. Our designed TPE-pHP-Cbl NPs exhibited the unique benefits such as (i) aggregation-induced emission enhancement, (ii) large Stoke’s shift, (iii) the photoirradiation wavelength >410 nm, (iv) the drug release occurs only in the aggregated state upon photolysis, (v) PDT activity, (vi) real-time monitoring of drug release by a noninvasive fluorescence color change approach, and (vii) PDT activity of the released photoproduct (TPE-pHP-OH), thereby resulting in the improved therapeutic efficiency. In vitro experiments show that TPE-pHP-Cbl NPs display excellent properties such as cellular imaging, synergistic combination therapy, and biocompatibility.
No takes yet. Share an insight, caveat, or question.
Parthiban et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: